Consistent with a mitogenic role for PR in breast cancer, an in vivo preclinical study [54,55] recently showed that MIF treatment actually prevented the development of mammary carcinogenesis in mice carrying a mutated BRCA1 gene [55]. This evidence concerns the gene BRCA1 and breast cancer.